Abbott Laboratories (ABT) Competitors $131.94 -1.66 (-1.24%) Closing price 07/11/2025 03:58 PM EasternExtended Trading$132.00 +0.06 (+0.05%) As of 07/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABT vs. DXCM, ISRG, TSLA, ABBV, BSX, ELV, ITGR, JNJ, MDT, and TMOShould you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), Boston Scientific (BSX), Elevance Health (ELV), Integer (ITGR), Johnson & Johnson (JNJ), Medtronic (MDT), and Thermo Fisher Scientific (TMO). Abbott Laboratories vs. Its Competitors DexCom Intuitive Surgical Tesla AbbVie Boston Scientific Elevance Health Integer Johnson & Johnson Medtronic Thermo Fisher Scientific Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings. Do institutionals & insiders have more ownership in ABT or DXCM? 75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ABT or DXCM? Abbott Laboratories has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Which has better valuation and earnings, ABT or DXCM? Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbott Laboratories$41.95B5.47$13.40B$7.7117.11DexCom$4.03B8.11$576.20M$1.3462.22 Does the media refer more to ABT or DXCM? In the previous week, Abbott Laboratories had 54 more articles in the media than DexCom. MarketBeat recorded 73 mentions for Abbott Laboratories and 19 mentions for DexCom. DexCom's average media sentiment score of 1.43 beat Abbott Laboratories' score of 0.83 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 41 Very Positive mention(s) 7 Positive mention(s) 14 Neutral mention(s) 6 Negative mention(s) 4 Very Negative mention(s) Positive DexCom 15 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ABT or DXCM more profitable? Abbott Laboratories has a net margin of 31.89% compared to DexCom's net margin of 12.90%. DexCom's return on equity of 30.05% beat Abbott Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Abbott Laboratories31.89% 19.01% 10.82% DexCom 12.90%30.05%10.00% Do analysts prefer ABT or DXCM? Abbott Laboratories currently has a consensus target price of $143.11, suggesting a potential upside of 8.46%. DexCom has a consensus target price of $98.50, suggesting a potential upside of 18.15%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Abbott Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abbott Laboratories 0 Sell rating(s) 6 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.76DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95 SummaryDexCom beats Abbott Laboratories on 10 of the 17 factors compared between the two stocks. Get Abbott Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABT vs. The Competition Export to ExcelMetricAbbott LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$232.44B$10.56B$5.62B$20.74BDividend Yield1.77%2.06%5.24%3.71%P/E Ratio17.1116.5428.1027.84Price / Sales5.4730.18429.7042.35Price / Cash20.3022.9637.4622.63Price / Book4.783.668.044.57Net Income$13.40B$235.43M$3.18B$989.30M7 Day Performance-1.31%1.27%3.61%0.20%1 Month Performance-3.22%2.95%4.04%3.95%1 Year Performance26.54%-15.74%29.99%10.27% Abbott Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABTAbbott Laboratories4.9559 of 5 stars$131.95-1.2%$143.11+8.5%+26.7%$232.44B$41.95B17.11114,000Trending NewsUpcoming EarningsAnalyst ForecastDXCMDexCom4.8227 of 5 stars$82.94+0.0%$98.50+18.8%-26.0%$32.53B$4.03B61.9210,300Positive NewsISRGIntuitive Surgical4.6833 of 5 stars$533.93-1.9%$588.95+10.3%+15.5%$191.36B$8.35B78.2815,638Positive NewsAnalyst ForecastTSLATesla4.6686 of 5 stars$294.10-6.7%$301.60+2.5%+30.1%$946.70B$95.72B161.49125,665Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionABBVAbbVie4.4969 of 5 stars$187.35-1.0%$211.29+12.8%+13.2%$330.93B$56.33B79.7255,000Trending NewsAnalyst RevisionBSXBoston Scientific4.657 of 5 stars$103.48-0.8%$116.09+12.2%+34.2%$153.09B$16.75B75.5353,000Trending NewsELVElevance Health4.9596 of 5 stars$346.59-0.4%$498.87+43.9%-36.3%$78.30B$177.01B13.52104,200Trending NewsUpcoming EarningsAnalyst ForecastITGRInteger2.4652 of 5 stars$116.55-3.7%$145.00+24.4%+2.1%$4.07B$1.72B55.2311,000News CoverageJNJJohnson & Johnson4.7716 of 5 stars$155.04-0.6%$170.88+10.2%+4.8%$373.04B$88.82B17.25138,100Trending NewsUpcoming EarningsAnalyst ForecastMDTMedtronic4.6166 of 5 stars$87.52-1.0%$97.87+11.8%+15.3%$112.25B$33.54B24.1895,000Trending NewsAnalyst ForecastGap UpTMOThermo Fisher Scientific4.9925 of 5 stars$417.62-2.7%$604.05+44.6%-19.8%$157.65B$42.88B24.49125,000Trending NewsDividend AnnouncementAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies DXCM Alternatives ISRG Alternatives TSLA Alternatives ABBV Alternatives BSX Alternatives ELV Alternatives ITGR Alternatives JNJ Alternatives MDT Alternatives TMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
